Canopus Biopharma Incorporated Stock Performance
| CBIA Stock | USD 0.0001 0.00 0.00% |
Canopus BioPharma holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.54, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Canopus BioPharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Canopus BioPharma is expected to be smaller as well. Use Canopus BioPharma jensen alpha, maximum drawdown, semi variance, as well as the relationship between the sortino ratio and potential upside , to analyze future returns on Canopus BioPharma.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Canopus BioPharma Incorporated are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat fragile forward indicators, Canopus BioPharma sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | -2.4 M |
Canopus |
Canopus BioPharma Relative Risk vs. Return Landscape
If you would invest 0.01 in Canopus BioPharma Incorporated on October 17, 2024 and sell it today you would earn a total of 0.00 from holding Canopus BioPharma Incorporated or generate 0.0% return on investment over 90 days. Canopus BioPharma Incorporated is currently generating 6.6667% in daily expected returns and assumes 40.6167% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Canopus, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Canopus BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Canopus BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Canopus BioPharma Incorporated, and traders can use it to determine the average amount a Canopus BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1641
| Best Portfolio | Best Equity | CBIA | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 40.62 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Canopus BioPharma is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Canopus BioPharma by adding it to a well-diversified portfolio.
Canopus BioPharma Fundamentals Growth
Canopus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Canopus BioPharma, and Canopus BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Canopus Pink Sheet performance.
| Shares Outstanding | 9.3 M | |||
| Cash Flow From Operations | 1.98 M | |||
| Total Asset | 1.56 M | |||
| Retained Earnings | (10.29 M) | |||
| Current Asset | 92 K | |||
| Current Liabilities | 2.36 M | |||
About Canopus BioPharma Performance
By analyzing Canopus BioPharma's fundamental ratios, stakeholders can gain valuable insights into Canopus BioPharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Canopus BioPharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Canopus BioPharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. Canopus BioPharma Incorporated is based in Santa Monica, California. Canopus Biopharma is traded on OTC Exchange in the United States.Things to note about Canopus BioPharma performance evaluation
Checking the ongoing alerts about Canopus BioPharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Canopus BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Canopus BioPharma is way too risky over 90 days horizon | |
| Canopus BioPharma has some characteristics of a very speculative penny stock | |
| Canopus BioPharma appears to be risky and price may revert if volatility continues |
- Analyzing Canopus BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Canopus BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Canopus BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Canopus BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Canopus BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Canopus BioPharma's pink sheet. These opinions can provide insight into Canopus BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Canopus Pink Sheet analysis
When running Canopus BioPharma's price analysis, check to measure Canopus BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Canopus BioPharma is operating at the current time. Most of Canopus BioPharma's value examination focuses on studying past and present price action to predict the probability of Canopus BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Canopus BioPharma's price. Additionally, you may evaluate how the addition of Canopus BioPharma to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |